Nuvisan joins IHI project LIGAND-AI to help advance AI-driven drug discovery through open science

Nuvisan is part of LIGAND-AI, a new Innovative Health Initiative (IHI) project led by Pfizer and the Structural Genomics Consortium (SGC). With 18 partners across nine countries and a budget exceeding €60 million, LIGAND-AI aims to generate large, open, high-quality datasets of protein–ligand interactions to train AI models capable of predicting drug-like molecules as binders for thousands of human proteins.  

“LIGAND-AI represents a transformative step in harnessing artificial intelligence and open science for digital drug discovery. By uniting world-class partners from industry and academia, we are building a foundation of high-quality data and developing innovative AI tools to accelerate the creation of life-changing medicines for patients worldwide,” said Franz von Nussbaum, President, Nuvisan. 

Charlotte Kopitz, President, Nuvisan, added: "Nuvisan is contributing to setting a new benchmark for open and standardised data generation in drug discovery. By creating comprehensive, high-quality datasets of protein–ligand interactions across thousands of human protein targets, we help empower researchers and AI innovators to advance the identification of effective therapies — supporting progress in science and society alike." 

This open-science collaboration represents a major step toward the mission of Target 2035 — developing pharmacological modulators for every human protein by 2035.